Tropical enteropathy is characterized by an increased urinary lactulose-to-mannitol (L:M) ratio on a site-specifi c sugar absorption test and is associated with increased intestinal permeability and decreased nutrient absorptive capacity. The etiology of tropical enteropathy is postulated to be intestinal bacterial overgrowth. This study tested the hypothesis that treatment with a nonabsorbable, broad-spectrum antibiotic, rifaximin, reduces the L:M ratio in rural Malawian children, among whom tropical enteropathy is common.
INTRODUCTION
Tropical enteropathy is characterized by a diff use villous atrophy of the small bowel associated with infl ammatory T-cell infi ltration (1 -4) and subclinical malabsorption. It is associated with stunting of otherwise healthy children who are < 5 years of age in developing countries (5) . Although tropical enteropathy is widely attributed to some environmental exposure (6) , the specifi c association is unknown. Given the high prevalence of tropical enteropathy in rural communities of developing countries (7) , hygiene may well play a role (8, 9) . Microbial contamination of food and water can lead to changes in the populations of enteric microbiota, and may lead to small-bowel bacterial overgrowth (10) that manifests as tropical enteropathy.
Damage to the normal intestinal architecture compromises the intestine ' s capacity to absorb macronutrients (11 -14) . Th e small-intestinal sugar-permeability test is a noninvasive means of assessing tropical enteropathy and correlates well with the severity of histological changes (15) , nutrient absorptive capacity (16, 17) , diarrhea (18) , and growth (5) . Traditionally, the 10.1038/ajg. 2009.270 A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin, a Nonabsorbable Antibiotic, in the Treatment of Tropical Enteropathy small-intestinal sugar-permeability test uses the non-metabolized sugars, mannitol and lactulose, which are administered orally and measured in the urine as the ratio of lactulose to mannitol (L:M) (19) . More recently, it has been shown that permeability can be measured in a site-specifi c manner using the additional sugars, sucrose and sucralose. Sucrose measures gastric permeability, the sucrose:lactulose ratio (SUC:L) measures proximal gastrointestinal permeability, sucralose measures whole-bowel permeability, and the sucralose:lactulose (SCL:L) ratio measures colonic permeability (20 -22) .
We explored the eff ect of rifaximin, a semi-synthetic nonabsorbable antibiotic with broad-spectrum activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria (23, 24) , in a population at high risk for tropical enteropathy. Rifaximin has shown some effi cacy for use in " traveler ' s diarrhea " (25, 26) , Clostridium diffi cile colitis (27) , infl ammatory bowel disease (28, 29) , and for the treatment of small-intestinal bacterial overgrowth (30, 31) . Given the experience with rifaximin in these diverse clinical problems provoked by alterations in the gut microbiota, and given the speculation that tropical enteropathy may be the result of small-intestinal bacterial overgrowth, we undertook a trial of 7 days of rifaximin in asymptomatic Malawian children, who were at high risk for tropical enteropathy, to test the hypothesis that rifaximin therapy would improve the L:M ratio compared with that with placebo. As gastric, proximal small-bowel and colonic permeability have not been evaluated in children with tropical enteropathy, we also explored the eff ect of rifaximin treatment on permeability in these sites as secondary outcomes.
METHODS

Subjects
Th is study was conducted in the village of Limela, located in the Machinga district of southern Malawi. Th e diet of the children there consists primarily of maize, supplemented with small amounts of fi sh. People live in mud huts with thatched roofs, and meals are prepared outdoors over open wood fi res. Local health care is provided by traditional healers or by government health-surveillance assistants who have completed 2 months of instruction in fi rst aid and disease prevention.
All children in Limela aged 3 -5 years were recruited for the study. Exclusion criteria included any chronic debilitating illnesses, such as cerebral palsy, or obvious congenital abnormalities. If a child was in need of acute medical treatment, arrangements were made for a visit with the local health staff . If a child showed any evidence of severe acute malnutrition (edema suggestive of kwashiorkor or a weight-for-height Z score < − 3), the child was excluded from the study and enrolled in a home-based therapeutic feeding program (32) .
Written and oral informed consent was obtained from each child ' s parent or caretaker before enrollment in the study by a native-speaking research nurse. Caretakers were free-to-end participation in the study at any time. Th e study was approved by the institutional review boards of both the University of Malawi and Washington University in St Louis (ClinicalTrials. gov number NCT00858988).
Study design
Th is study was a randomized, double-blinded, placebo-controlled trial of the effi cacy of rifaximin to reduce tropical enteropathy. All participants were enrolled on the same day in September 2007. Initial demographic information was collected about the child ' s household, including whether the child ' s mother and father were alive and what type of water source was available to the household. Initial anthropometric information collected included an evaluation for edema and measurements of weight, height, and mid-upper-arm circumference. Information was also collected regarding the number of days of diarrhea, visible blood in stool, abdominal pain, vomiting, cough, and rash during the earlier week. Aft er the collection of this information, each child completed the preintervention site-specifi c sugar-absorption test.
Starting from the morning aft er the site-specifi c sugarabsorption test, each child received for 7 consecutive days either 100 mg rifaximin (Salix Pharmaceuticals Inc., Morrisville, NC) or a starch placebo,twice daily, under the direct supervision of the fi eld research staff . Th e medication was given as a fl avored solution with water in a 30 ml cup, and the child was observed to consume the entire amount. Th e randomization to rifaximin or placebo was carried out prospectively with the use of a coded list compiled from a random number generator; the code was fully blinded to the fi eld staff and trial participants. A total of 150 small plastic sacks with either rifaximin or placebo were then prepared and numbered ahead of time in accordance with the list generated by a pharmacy student who had no contact with the children or the researchers in the fi eld. Th e rifaximin and placebo were indistinguishable in appearance and taste so that the children and fi eld staff had no knowledge of each child ' s allocation status to intervention or placebo. Th e code list was unblinded only aft er all the clinical and laboratory analyses were completed and data analysis was undertaken. Each child was visited at home 14 and 21 days aft er the start of the study to check on the child ' s clinical status, assess for side eff ects, and collect symptom information from the preceding week. Finally, the children returned to the research site in the village 28 days aft er starting treatment for a second site-specifi c sugar-absorption test and for anthropometric assessment.
Th e primary outcome was the diff erence in the urinary L:M ratio before and aft er the intervention. Secondary outcomes were the amounts of lactulose, mannitol, sucralose, and sucrose excreted in the urine as a percentage of the amount ingested before and aft er the intervention and changes in SUC:L and SCL:L. Adverse drug eff ects were monitored and included the incidence of diarrhea, bloody stool, abdominal pain, vomiting, cough, and rash.
A sample size of 128 was calculated as being necessary to detect a decrease of 0.06 units in the L:M ratio, with 95 % specifi city and 80 % power. Th is decrease was chosen because such a change would correlate well with a clinically signifi cant improvement in gut function. Th e sample size calculations assumed that urinary mannitol and lactulose measurements would be distributed in a manner similar to our earlier study, which showed that >70 % of apparently healthy rural Malawian children had tropical enteropathy (33) .
Site-specifi c sugar-absorption test
Caretakers were instructed to not give their children any food aft er 10 p.m. on the day before the site-specifi c sugar-absorption tests and to assemble at the village research site at 6 a.m. on the day of the tests. Aft er arrival at the research site, each child voided and this urine was collected and discarded.
To initiate the test, each child drank a 100 ml sugar solution containing 5 g lactulose, 1 g mannitol, 1 g sucralose, and 10 g sucrose. Th is sugar solution tastes quite sweet and all the children drank the solution eagerly. Th e children remained at the village research site for 4 h aft er ingestion of the sugar solution, during which time all of the child ' s urine was collected in a sterile cup with 10 mg merthiolate added to limit the bacterial degradation of excreted sugars. To facilitate the collection of urine, the children were given additional water to drink 3.5 h aft er ingestion of the sugar solution. During the 4 h collection time, the children were supervised at the research site by their mothers or by other guardians and the fi eld research staff , so that no urine is lost. Th ey were kept entertained with games and songs to help facilitate their cooperation in having to remain in a relatively small area for so long a time. When the children voided at least 4 h aft er the consumption of the sugar solution, they completed the urine collection and were dismissed. At the end of the collection period, the total urine volume was measured and a 4 ml aliquot was transferred into a plastic cryovial. Urine specimens were fl ash frozen, transported in a liquid nitrogen dry shipper, and stored in − 70 ° C freezers.
Th e concentrations of lactulose, mannitol, sucralose, and sucrose in the urine specimens were then analyzed as described earlier (22, 33) . For the analyses of sucrose, lactulose, and mannitol, a 20 μ l aliquot of spun urine was injected into an Aminex HPX 87C 300 7.8 mm cation-exchange column and eluted with degassed pure water at a fl ow rate of 0.6 ml / min at 85 ° C. Th e column effl uent was monitored with a diff erential refractometer (Dionex Corperation, Sunnyvale, CA), with the internal temperature set at 50 ° C. For the analysis of sucralose, the samples were processed through reverse solid-phase extraction using the " On Guard II RP 1 cc Cartridge " (Dionex Corporation, Sunnyvale, CA) to remove the majority of the background contaminants before being injected into the same analytical column but equipped with a " Carbo-C Cartridge " (BioRad Laboratories, Richmond, CA). Th e cartridge was washed with 5 ml of HPLC grade acetonitrile, and then with 5 ml of nanopure water, before applying 0.5 ml of the sample. Th e cartridge was then washed with 5 ml of nanopure water, followed by 0.3 ml of HPLC grade acetonitrile. Th e sucralose was eluted with 5 ml of HPLC grade acetonitrile. Th e effl uent was evaporated to dryness and then reconstituted in 0.5 ml of nanopure water. A 20 μ l aliquot was injected into the analytical column for analysis. Th e assays are sensitive to 1 μ g / ml of sucrose, lactulose, and mannitol, and to 10 μ g / ml of sucralose.
Statistical analysis
Data were tabulated on a spreadsheet, the randomization code was broken, and summary statistics were calculated for the groups that received rifaximin and placebo. Th e values for urinary sugar recovery were expressed as a percentage of the ingested dose. Th e reported values for normal L:M range from 0.03 to 0.12 (14, 16) . A value of ≥ 0.10 was chosen to be indicative of tropical enteropathy (14, 33) .
The differences in urinary sugar recovery and the sugar ratios before and after intervention were calculated and compared between the rifaximin and placebo groups by using the Wilcoxon rank-sum test. This nonparametric test was chosen because the ratios were not likely to be normally distributed, and the range of values includes only positive numbers. The changes in weight were compared using Student ' s t -test. The incidences of diarrhea, visible blood in stool, abdominal pain, vomiting, cough, and rash were compared using Fisher ' s exact test. For each comparison, P < 0.05 was considered statistically significant. Statistical analyses were carried out using the Excel (Microsoft Corp., Redmond, WA) and SPSS (SPSS, Inc., Chicago, IL) software packages.
RESULTS
A total of 147 children met the inclusion criteria and completed the study; 74 were in the rifaximin group and 73 were in the placebo group. Th e urine specimens for two children in the rifaximin group and for one child in the placebo group could not be used for calculation of the L:M ratio because no lactulose was detected in the urine. Th ese children were excluded from further analysis, leaving 72 children in each group ( Figure 1 ) . Th e baseline demographic, anthropometric, and clinical characteristics of the two groups did not diff er signifi cantly ( Table 1 ) . No children terminated the study early and all 144 children included in the analysis received their study intervention on all 7 days under the direct observation of study staff , except for one child who missed one dose of the intervention.
Upon enrollment, 108 (76 % ) of the children had an L:M ratio ≥ 0.10 beforethe intervention and 48 (34 % ) had an L:M ratio ≥ 0.20. Th e distribution of the L:M ratio ( Figure 2 ) and the change in the L:M ratio aft er intervention ( Figure 3 ) did not diff er signifi cantly aft er the intervention in either group. Th e administration of rifaximin for 7 days did not aff ect lactulose, mannitol, sucralose, or sucrose excretion, or the SUC: L or SCL:L ratios, in either the rifaximin or the placebo groups ( Table 2 ) .
Comparing only the children with an elevated L:M ratio on enrollment, the changes in the L:M ratio before and
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aft er treatment with rifaximin ( n = 53) or placebo ( n = 55) were − 0.03 ± 0.12 and − 0.02 ± 0.14, respectively ( P = 0.43). Likewise, the changes in SUC:L were − 0.026 ± 0.38 and − 0.031 ± 0.39, respectively, ( P = 0.94) and those in SCL:L were − 0.48 ± 3.46 and − 0.87 ± 2.99, respectively, ( P = 0.53).
Th e incidence of diarrhea during the study was higher in the rifaximin group compared with that in the placebo group (13 vs. 1 % , respectively) ( Table 3 ). Of the nine children in the rifaximin group who reported to have diarrhea during the study period, only one child had diarrhea during the fi rst week while they were receiving rifaximin. Two additional children had diarrhea during the third week, one during both the third and fourth weeks, and fi ve during the fi nal week. Th e child with diarrhea in the placebo group reported symptoms during the third week. None of the episodes of diarrhea were clinically dehydrating and did not lead any of the caregivers to seek additional health care for their children. Th ere was no clinical evidence of any other adverse eff ects in any of the children in the study by the time of fi nal evaluation on the last day of the study.
Among the 34 children with a L:M ratio < 0.10, which was considered normal, the SCL:L ratio was 0.60 ± 0.33 on enrollment.
DISCUSSION
In an impoverished rural African population of 3 -5-year-old children, of whom 76 % had evidence of tropical enteropathy, a 7-day course of rifaximin, given in the context of a rigorous, double-blind, placebo-controlled trial, had no eff ect on intestinal absorptive dysfunction, as measured by the sitespecifi c sugar-absorption test. Th is result suggests that intestinal bacterial overgrowth does not play a causal role in tropical enteropathy.
A limitation of the trial is that it was conducted in a rural subSaharan population in which corn is the staple food. In other populations with diff erent habitual diets, environmental conditions, or the prevalence of intestinal conditions such as celiac disease, the fi ndings may diff er. Th e baseline measurements of the L:M ratio in the present population are very similar to that found earlier in a diff erent Malawian village, but with similar environmental and dietary conditions (33) , showing the reproducibility of the sugar-absorption method.
Th e use of sucralose in the site-specifi c absorption test has not been performed earlier in a developing world population. Sucralose serves as a useful marker of colonic permeability in individuals in whom the the L:M ratio is normal (21, 22, 34) . urine from these young children in the fi eld. We thus chose a 4 h time frame for urine collection as a compromise between these confl icting demands. Th ere has been little experience with regard to the use of sucrose in a site-specifi c absorption test from the developing world; one other similar population in Malawi studied by our research group found a value for sucrose excretion to be 0.06 % , very similar to the value found in this study. In healthy control populations of older children from the developed world, 0.02 -0.03 % of administered sucrose has been recovered in the urine. We speculate that this fi nding may represent modest, subclinical gastritis in this population, which could be the consequence of a Helicobacter pylori infection. Th e fi nding that urinary sucrose excretion is increased in Malawian children requires further investigation to understand its signifi cance.
Although it has been suggested that tropical enteropathy is the result of bacterial overgrowth, the use of antibiotics in Earlier work in healthy American children has shown that 0.4 % of sucralose is recovered in the urine aft er 3 h and that a normal SCL:L value is approximately 0.8 (20) . In comparison, 0.5 % of sucralose was recovered in the urine in this study and the SCL:L ratio was approximately half of that seen in healthy American children. Some of these diff erences may be attributed to diff erences in methodology. In this study, urinary sugar recovery was determined over 4 h, whereas earlier data were collected in a 3 h urine collection, and sucralose can be expected to enter the body through the largest absorptive surface, the small bowel, which had increased permeability in our population. Th e similar fraction of sucralose recovered in the urine, however, and the lower SCL:L ratio indicate that colonic permeability was not increased in rural Malawian children. To fully evaluate the colonic permeability of sucralose, a longer time period for urine collection may have been helpful (21) , but this would add signifi cant complexity to the collection of Diarrhea in the week before study ( n ( % ))
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Rifaximin for Tropical Enteropathy a clinical trial in children with tropical enteropathy has not been reported earlier. We chose to use rifaximin because of its safety, lack of systemic absorption, and broad-spectrum of antibacterial activity (23, 35) . A single-dosing regimen of rifaximin for a fi xed duration was used, and thus a doseresponse eff ect could not be specifi cally studied. Th e rifaximin dose used in adults was 400 -800 mg / day for 3 -5 days (23 -25,28,35) ; it can be reasonably extrapolated that the dose of 200 mg / day for 7 days used with young children in this study was suffi cient to achieve a comparable drug exposure in the intestinal tract. Allowing for a 21-day period before the reassessment of tropical enteropathy aft er the completion of intervention provided time for the regeneration of healthy enterocytes and for the restoration of the intestinal absorptive area. It seems unlikely that trials using diff erent antibiotics or with the L:M ratio measured at diff erent intervals would have a fundamentally diff erent result. Th e greater number of children who received rifamixin and who reported diarrhea was not signifi cantly diff erent from the fraction of children reported to have diarrhea in the week before intervention, nor was the diarrhea clinically serious. Administration of antibiotics oft en results in subclinical changes in stool patterns, so this fi nding is not unexpected. In addition, this fi nding may simply be one of chance, given that it was observed 2 weeks aft er medication had ceased. Further monitoring of diarrhea among children receiving rifaximin is warranted, given the limited experience with this drug in children.
Th is study should lead to a reconsideration of the hypothesis that overgrowth or disruption of the normal bacterial microbiota in the small bowel leads to tropical enteropathy in an environment in which the consumption of coliform-contaminated foods is common. It is apparent that the perturbations causing tropical enteropathy occur in the small bowel; the site-specifi c test for colonic and stomach permeability did not show marked derangements, and earlier work shows that the probiotic Lactobacillus GG off ers no benefi t in alleviating tropical enteropathy (33) . Rifaximin has shown eff ectiveness in reducing small-bowel bacterial overgrowth; if a similar pathophysiological process were at work in tropical enteropathy, rifaximin should have been eff ective in this clinical setting 
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WHAT IS CURRENT KNOWLEDGE
3 Tropical enteropathy is associated with stunting the growth of otherwise healthy children in developing countries.
3 The etiology of tropical enteropathy is not understood.
3 One hypothesis is that small-bowel bacterial overgrowth leads to tropical enteropathy.
as well. Our data suggest that eff orts to improve hygiene aimed at reducing coliform contamination of the diet may not aff ect tropical enteropathy. Given that an acute enteric infection because of viral and parasitic pathogens can also compromise intestinal mucosal integrity (18) , perhaps chronic or repeated infections with nonbacterial organisms is linked to tropical enteropathy. Clinical studies to test this hypothesis may thus be warranted. For example, infection because of intestinal parasites could be correlated with intestinal integrity, or a trial carried out of empirical treatment with an antiparasitic agent (6) . A specifi c study to detail the populations of bacteria present among the enteric microbiota (36) of children with and without tropical enteropathy may be helpful in determining the role that bacterial communities play in this process.
Recent evidence indicates that intestinal permeability is modulated by the human immune system, and that intestinal permeability plays an important role in allergic and autoimmune disease (37) . Th e role of cell-mediated immunity, particularly specifi c T-cell subsets and cytokines, in the pathogenesis of tropical enteropathy may well be an important additional area for research.
Th e failure of empirical antibacterial therapy to improve tropical enteropathy suggests that nutritional etiologies must also be considered in the pathogenesis of tropical enteropathy. A supplementation trial of the micronutrients, vitamin A and zinc, in Brazilian children was eff ective in improving the intestinal barrier function and also correlated with an improvement in linear growth (17) . An inadequate intake of macronutrients may play a role in the pathogenesis of tropical enteropathy, although the observation that enteropathy is prevalent in residents of the developing world who are of every socio-economic class and ethnic background makes this seem less plausible. Longitudinal studies evaluating the role of nutritional status and nonbacterial microbes are needed to elucidate the pathophysiology of this disease process.
